Wells Fargo & Company Enlivex Therapeutics Ltd. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 9,184 shares of ENLV stock, worth $11,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,184

Previous 9,993 8.1%

Holding current value

$11,939

Previous $37,000 64.86%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.27 - $4.31 $1,027 - $3,486	-809 Reduced 8.1%	9,184 $13,000
Q4 2023 Feb 09, 2024	BUY	$1.29 - $2.92 $1,433 - $3,244	1,111 Added 12.51%	9,993 $26,000
Q2 2023 Aug 15, 2023	SELL	$2.51 - $3.71 $4,553 - $6,729	-1,814 Reduced 16.96%	8,882 $23,000
Q1 2023 May 12, 2023	SELL	$3.41 - $4.55 $3,580 - $4,777	-1,050 Reduced 8.94%	10,696 $38,000
Q4 2022 Feb 13, 2023	SELL	$3.74 - $4.81 $23,591 - $30,341	-6,308 Reduced 34.94%	11,746 $46,000
Q3 2022 Nov 14, 2022	BUY	$4.11 - $5.87 $23,348 - $33,347	5,681 Added 45.91%	18,054 $77,000
Q2 2022 Aug 12, 2022	SELL	$3.81 - $8.64 $12,348 - $28,002	-3,241 Reduced 20.76%	12,373 $56,000
Q1 2022 May 16, 2022	BUY	$4.92 - $6.66 $16,777 - $22,710	3,410 Added 27.94%	15,614 $87,000
Q4 2021 Feb 14, 2022	SELL	$5.81 - $9.73 $5,600 - $9,379	-964 Reduced 7.32%	12,204 $76,000
Q3 2021 Nov 15, 2021	SELL	$7.43 - $13.86 $46,979 - $87,636	-6,323 Reduced 32.44%	13,168 $130,000
Q2 2021 Aug 16, 2021	BUY	$8.61 - $12.1 $12,915 - $18,150	1,500 Added 8.34%	19,491 $174,000
Q1 2021 May 13, 2021	BUY	$9.26 - $24.0 $164,744 - $426,984	17,791 Added 8895.5%	17,991 $199,000
Q4 2020 Feb 09, 2021	BUY	$8.16 - $14.5 $1,632 - $2,900	200 New	200 $2,000

Others Institutions Holding ENLV

# of Institutions

Shares Held

2.13M

Call Options Held

16.1K

Put Options Held

3.4K

View Full List

About Enlivex Therapeutics Ltd.

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23.9M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

More about ENLV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Enlivex Therapeutics Ltd. Transaction History